ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ラスミジタン

Lasmiditan

HCID 11610526
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
439239-90-4
標準SMILES
CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1
InChIKey
XEDHVZKDSYZQBF-UHFFFAOYSA-N
分子式
C19H18F3N3O2
平均分子量
377.4 g/mol
単同位体質量
377.13511131

概要

Lasmiditan is a DEA Schedule V controlled substance. Substances in the DEA Schedule V have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics. It is a Depressants substance.

名称と識別子

優先名称
Lasmiditan
IUPAC
2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridinyl]benzamide
現地名
ラスミジタン
英語名
LasMiditan
分子式
C19H18F3N3O2
分子量
377.36

名称と別名

Lasmiditan439239-90-4COL-1442,4,6-Trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl)benzamide2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamideCOL 144760I9WM792DTXSID40469435lasmiditanumRefChem:58578DTXCID002034182,4,6-trifluoro-n-(6-((1-methylpiperidin-4-yl)carbonyl)pyridin-2yl)benzamide
名称をさらに表示
2,4,6-トリフルオロ-N-(6-(1-メチルピペリジン-4-カルボニル)ピリジン-2-イル)ベンズアミドラスミジタン2,4,6-トリフルオロ-N-[6-[(1-メチル-4-ピペリジニル)カルボニル]-2-ピリジル]ベンズアミド2,4,6-トリフルオロ-N-[6-(1-メチルピペリジン-4-カルボニル)ピリジン-2-イル]ベンズアミドLasMiditan (COL-1442,4-difluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl)benzamideCS-2381LamiditamLamiditanLasmiditant13C-Lasmiditan
MFCD18633238ReyvowLY573144lasmitidan2,4,6-Trifluoro-N-(6-((1-methylpiperidine-4-yl)carbonyl)pyridin-2-yl)benzamide2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridinyl]benzamide2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide2,4,6-tris(fluoranyl)-N-[6-(1-methylpiperidin-4-yl)carbonylpyridin-2-yl]benzamide

物性

構造計算による物性補完中

XLogP
2.8
極性表面積
62.3 Ų
水素結合供与体数
1
水素結合受容体数
7
回転可能結合数
4
重原子数
27
形式電荷
0
複雑度
530

実験および物理化学的性質

Drugs · 3 件

DEA Schedule V Controlled Substance -> Depressants

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Unknown

Human Drugs · 3 件

Breast Feeding; Lactation; Serotonin Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Vasoconstrictor Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

物理化学的性質

融点
255 ℃ · 255℃
沸点
433.3 · 433.3±45.0 °C(Predicted)
比重(密度)
1.351 · 1.351
貯蔵温度
-20 °C · -20°C Freezer, Under inert atmosphere
溶解性
クロロホルム(微量)、DMSO(微量)
酸解離定数(Pka)
9.91 · 9.91±0.70(Predicted)
外見
個体
色
ホワイトからオフホワイト

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

危険有害性情報

Regulatory InformationDEA schedule V controlled substance

毒性情報

Hepatotoxicity · 1 件

In preregistration controlled trials of lasmiditan in several thousand patients, mild-to-moderate serum aminotransferase elevations arose in a small percentage of patients (1% or less) and overall rates were not different from those in placebo recipients. In the controlled trials and subsequently with general use, there have been no reports of liver injury with symptoms or jaundice attributed to lasmiditan.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H319

化学と産業

薬理情報

ATC Code · 2 件

N - Nervous system

QN - Nervous system

Protein BindingLasmiditan exhibits a concentration-independent plasma protein binding of approximately 55-60%.
Pharmacodynamics · 1 件

Lasmiditan belongs to a new and novel class of acute anti-migraine medications that exert their effects via inhibition of neuronal firing rather than vasoconstriction of cerebral arteries. Lasmiditan appears to have a relatively quick onset of action (an important characteristic in acute migraine treatment) with some patients reporting benefit within 20 minutes. Due to its ability to cause CNS depression (e.g. drowsiness, dizziness), lasmiditan may cause significant driving impairment and patients should be advised not to participate in activities requiring mental alertness for at least 8 hours after dosing. Lasmiditan may carry some potential for abuse and should be used with caution in patients who may be at risk of drug abuse - its controlled substance scheduling is currently under review in the United States by the Drug Enforcement Administration (DEA). The safety of lasmiditan in pregnancy is unknown and is currently being monitored with a pregnancy exposure registry created by Eli Lilly and Company.

Mechanism of Action · 1 件

The acute treatment of migraine headaches has, in the past, been achieved via constriction of cerebral blood vessels, as the acute dilation of these vessels observed during migraines was thought to be the cause of the associated pain. The neurogenic hypothesis of migraine pathophysiology, an alternative to the vascular hypothesis, suggests that cerebral vasodilation is a secondary mechanism in migraine pathogenesis, and that the main contributor to migraine headache pain is the increased pathogenic firing of trigeminal nerve pathways. While the precise mechanism of action of lasmiditan is unclear, it likely supports this neurogenic hypothesis by exerting its therapeutic effects through potent and selective agonism of the 5-HT<sub>1F</sub> receptor. 5-HT<sub>1F</sub> receptors are found in both the central and peripheral nervous system (on the central and peripheral ends of trigeminal neurons) and appear to contribute to hyperpolarization of nerve terminals and inhibition of trigeminal neuronal activity. Lasmiditan's agonism at these receptors may, therefore, inhibit the firing of trigeminal nerves responsible for migraine headache pain. Lasmiditan has virtually no affinity for other 5-HT receptor subtypes or monoamine receptors (e.g. adrenergic, dopaminergic).

関連反応

14 件
反応記録を作成
HRID 30219 の反応式
HRID 30219反応物として
HRID 30225 の反応式
HRID 30225反応物として
HRID 404239 の反応式
HRID 404239反応物として
HRID 404245 の反応式
HRID 404245反応物として
HRID 666419 の反応式
HRID 666419生成物として
HRID 685587 の反応式
HRID 685587反応物として
HRID 1667344 の反応式
HRID 1667344反応物として
HRID 1667350 の反応式
HRID 1667350反応物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
439239-90-4
PubChem CID
11610526
DTXSID
DTXSID40469435
ChEMBL
CHEMBL3039520
UNII
760I9WM792
Nikkaji
J2.994.454G
Biological Half-LifeThe mean elimination half-life of lasmiditan is 5.7 hours.
Metabolism/Metabolites · 1 件

The hepatic and extra-hepatic metabolism of lasmiditan is catalyzed primarily by non-CYP enzymes, with ketone reduction appearing to be the primary pathway. While the specific enzymes involved in the metabolism of lasmiditan have not been elucidated, FDA labeling states that the following enzymes are _not_ involved in its metabolism: monoamine oxidases, CYP450 reductase, xanthine oxidase, alcohol dehydrogenase, aldehyde dehydrogenase, and aldo-keto reductases. The metabolites of lasmiditan have not been characterized in published research, but two of its metabolites (M7 and M18) are considered to be pharmacologically inactive.

MeSH Pharmacological ClassificationEndogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS.
Absorption, Distribution and Excretion · 3 件

Oral absorption of lasmiditan is quick, with a median tmax of 1.8 hours. An open-label study looking at absorption pharmacokinetics found the Cmax and AUC0-t of lasmiditan following oral administration to be 322.8 ± 122.0 ng/mL and 1892 ± 746.0 ng.h/mL, respectively. The oral bioavailability of lasmiditan has been reported as approximately 40%. Co-administration of lasmiditan with a high-fat meal increased its Cmax and AUC by 22% and 19%, respectively, and delayed Tmax by approximately 1 hour - these differences in absorption are relatively minor and unlikely to be clinically significant. Similarly, severe renal impairment and mild-moderate hepatic impairment were found to increase both AUC and Cmax, but not to a clinically significant extent.

Lasmiditan is eliminated primarily via metabolism, with renal excretion accounting for a small fraction of its total elimination. Of the small amount of drug found in the urine post-dose, approximately 66% is comprised of lasmiditan's S-M8 metabolite. Only 3% of an administered dose of lasmiditan was recovered unchanged in the urine, further implying a relatively extensive metabolism of this drug.

Lasmiditan has been shown to penetrate the blood-brain barrier.

応用分野 · 2 件

説明Lasmiditan (Item No. 28369) is an analytical reference standard categorized as an agonist of the serotonin (5-HT) receptor subtype 5-HT1F. Formulations containing lasmiditan have been used in the treatment of migraine headache. Lasmiditan has low abuse potential. Lasmiditan is regulated as a Schedule V compound in the United States. This product is intended for research and forensic applications.

使用Lasmiditan is used in diagnosing, treating and/or preventing periodontal disease and/or tooth loss.

上流・下流製品情報

上流原料

N-Methoxy-N,1-diMethylpiperidine-4-carboxaMide(6-アミノピリジン-2-イル)(1-メチルピペリジン-4-イル)メタノン2-アミノ-6-ブロモピリジン塩化2,4,6-トリフルオロベンゾイル1-メチルピペリジン-4-カルボニルクロリド1-メチルピペリジン-4-カルボン4-クロロ-1-メチルピペリジン